Cargando…
Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study
Background: Transmembrane tumor necrosis factor (TNF) receptors are involved in inflammatory, apoptotic, and proliferative processes. In the bloodstream, soluble TNF receptor II (sTNFR2) can modify the inflammatory response of immune cells and is predictive of cardiovascular disease risk. We hypothe...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928448/ https://www.ncbi.nlm.nih.gov/pubmed/29740313 http://dx.doi.org/10.3389/fphar.2018.00207 |
_version_ | 1783319245611859968 |
---|---|
author | Mendelson, Michael M. Johannes, Roby Liu, Chunyu Huan, Tianxiao Yao, Chen Miao, Xiao Murabito, Joanne M. Dupuis, Josée Levy, Daniel Benjamin, Emelia J. Lin, Honghuang |
author_facet | Mendelson, Michael M. Johannes, Roby Liu, Chunyu Huan, Tianxiao Yao, Chen Miao, Xiao Murabito, Joanne M. Dupuis, Josée Levy, Daniel Benjamin, Emelia J. Lin, Honghuang |
author_sort | Mendelson, Michael M. |
collection | PubMed |
description | Background: Transmembrane tumor necrosis factor (TNF) receptors are involved in inflammatory, apoptotic, and proliferative processes. In the bloodstream, soluble TNF receptor II (sTNFR2) can modify the inflammatory response of immune cells and is predictive of cardiovascular disease risk. We hypothesize that sTNFR2 is associated with epigenetic modifications of circulating leukocytes, which may relate to the pathophysiology underlying atherogenic risk. Methods: We conducted an epigenome-wide association study of sTNFR2 levels in the Framingham Heart Study Offspring cohort (examination 8; 2005–2008). sTNFR2 was quantitated by enzyme immunoassay and DNA methylation by microarray. The concentration of sTNFR2 was log(e)-transformed and outliers were excluded. We conducted linear mixed effects models to test the association between sTNFR2 level and methylation at over 400,000 CpGs, adjusting for age, sex, BMI, smoking, imputed cell count, technical covariates, and accounting for familial relatedness. Results: The study sample included 2468 participants (mean age: 67 ± 9 years, 52% women, mean sTNFR2 level 2661 ± 1078 pg/ml). After accounting for multiple testing, we identified 168 CpGs (P < 1.2 × 10(-7)) that were differentially methylated in relation to sTNFR2. A substantial proportion (27 CpGs; 16%) are in the major histocompatibility complex region and in loci overrepresented for antigen binding molecular functions (P = 1.7 × 10(-4)) and antigen processing and presentation biological processes (P = 1.3 × 10(-8)). Identified CpGs are enriched in active regulatory regions and associated with expression of 48 cis-genes (±500 kb) in whole blood (P < 1.1 × 10(-5)) that coincide with genes identified in GWAS of diseases of immune dysregulation (inflammatory bowel disease, type 1 diabetes, IgA nephropathy). Conclusion: Differentially methylated loci in leukocytes associated with sTNF2 levels reside in active regulatory regions, are overrepresented in antigen processes, and are linked to inflammatory diseases. |
format | Online Article Text |
id | pubmed-5928448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59284482018-05-08 Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study Mendelson, Michael M. Johannes, Roby Liu, Chunyu Huan, Tianxiao Yao, Chen Miao, Xiao Murabito, Joanne M. Dupuis, Josée Levy, Daniel Benjamin, Emelia J. Lin, Honghuang Front Pharmacol Pharmacology Background: Transmembrane tumor necrosis factor (TNF) receptors are involved in inflammatory, apoptotic, and proliferative processes. In the bloodstream, soluble TNF receptor II (sTNFR2) can modify the inflammatory response of immune cells and is predictive of cardiovascular disease risk. We hypothesize that sTNFR2 is associated with epigenetic modifications of circulating leukocytes, which may relate to the pathophysiology underlying atherogenic risk. Methods: We conducted an epigenome-wide association study of sTNFR2 levels in the Framingham Heart Study Offspring cohort (examination 8; 2005–2008). sTNFR2 was quantitated by enzyme immunoassay and DNA methylation by microarray. The concentration of sTNFR2 was log(e)-transformed and outliers were excluded. We conducted linear mixed effects models to test the association between sTNFR2 level and methylation at over 400,000 CpGs, adjusting for age, sex, BMI, smoking, imputed cell count, technical covariates, and accounting for familial relatedness. Results: The study sample included 2468 participants (mean age: 67 ± 9 years, 52% women, mean sTNFR2 level 2661 ± 1078 pg/ml). After accounting for multiple testing, we identified 168 CpGs (P < 1.2 × 10(-7)) that were differentially methylated in relation to sTNFR2. A substantial proportion (27 CpGs; 16%) are in the major histocompatibility complex region and in loci overrepresented for antigen binding molecular functions (P = 1.7 × 10(-4)) and antigen processing and presentation biological processes (P = 1.3 × 10(-8)). Identified CpGs are enriched in active regulatory regions and associated with expression of 48 cis-genes (±500 kb) in whole blood (P < 1.1 × 10(-5)) that coincide with genes identified in GWAS of diseases of immune dysregulation (inflammatory bowel disease, type 1 diabetes, IgA nephropathy). Conclusion: Differentially methylated loci in leukocytes associated with sTNF2 levels reside in active regulatory regions, are overrepresented in antigen processes, and are linked to inflammatory diseases. Frontiers Media S.A. 2018-04-24 /pmc/articles/PMC5928448/ /pubmed/29740313 http://dx.doi.org/10.3389/fphar.2018.00207 Text en Copyright © 2018 Mendelson, Johannes, Liu, Huan, Yao, Miao, Murabito, Dupuis, Levy, Benjamin and Lin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Mendelson, Michael M. Johannes, Roby Liu, Chunyu Huan, Tianxiao Yao, Chen Miao, Xiao Murabito, Joanne M. Dupuis, Josée Levy, Daniel Benjamin, Emelia J. Lin, Honghuang Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study |
title | Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study |
title_full | Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study |
title_fullStr | Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study |
title_full_unstemmed | Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study |
title_short | Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study |
title_sort | epigenome-wide association study of soluble tumor necrosis factor receptor 2 levels in the framingham heart study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928448/ https://www.ncbi.nlm.nih.gov/pubmed/29740313 http://dx.doi.org/10.3389/fphar.2018.00207 |
work_keys_str_mv | AT mendelsonmichaelm epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT johannesroby epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT liuchunyu epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT huantianxiao epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT yaochen epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT miaoxiao epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT murabitojoannem epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT dupuisjosee epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT levydaniel epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT benjaminemeliaj epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy AT linhonghuang epigenomewideassociationstudyofsolubletumornecrosisfactorreceptor2levelsintheframinghamheartstudy |